<p>The roll out of Russian Covid-19 vaccine Sputnik V at Indraprastha Apollo and Madhukar Rainbow Children's Hospital in Delhi has been delayed for some days, officials said on Sunday.</p>.<p>A spokesperson of Apollo Hospitals said the facility in Delhi will tentatively start administering the two-dose vaccine by June 25.</p>.<p>An official had earlier said the hospital would start giving Sputnik V jabs by June 20.</p>.<p><strong>Read more: <a href="https://www.deccanherald.com/national/north-and-central/delhi-eases-covid-19-curbs-further-bars-to-reopen-tomorrow-999454.html" target="_blank">Delhi eases Covid-19 curbs further: Bars to reopen tomorrow </a></strong></p>.<p>According to an official of Madhukar Rainbow Children's Hospital, there is a delay on the part of the suppliers.</p>.<p>"We are expecting (roll out) next week," he said.</p>.<p>Fortis Healthcare, which had said it would make Sputnik V available at its Gurgaon and Mohali hospitals from Saturday, also has not started administering the Russian vaccine so far.</p>.<p>"The roll out did not happen on Saturday. We expect there will be some clarity on Monday," an official said.</p>.<p>The Centre has fixed the price of the vaccine at Rs 1,145 per dose. The maximum price of Covishield for private Covid-19 Vaccination Centres (CVCs) has been fixed at Rs 780 per dose, while that of Covaxin is Rs 1,410 per dose.</p>.<p>Russia's Gamaleya National Research Institute of Epidemiology and Microbiology has developed Sputnik V and the Russian Direct Investment Fund (RDIF) is marketing it globally.</p>.<p>Hyderabad-based Dr Reddy's Laboratories, the marketing partner for the vaccine in the country, has been importing the shots from Russia. </p>.<p>Over a period of time, the vaccine is also going to be manufactured in India. </p>.<p>Sputnik V uses two different viruses that cause the common cold (adenovirus) in humans. It employs a different vector for each of the two shots, given 21 days apart.</p>.<p>According to Gamaleya and the RDIF, Sputnik V has demonstrated an efficacy rate of 92 per cent. </p>
<p>The roll out of Russian Covid-19 vaccine Sputnik V at Indraprastha Apollo and Madhukar Rainbow Children's Hospital in Delhi has been delayed for some days, officials said on Sunday.</p>.<p>A spokesperson of Apollo Hospitals said the facility in Delhi will tentatively start administering the two-dose vaccine by June 25.</p>.<p>An official had earlier said the hospital would start giving Sputnik V jabs by June 20.</p>.<p><strong>Read more: <a href="https://www.deccanherald.com/national/north-and-central/delhi-eases-covid-19-curbs-further-bars-to-reopen-tomorrow-999454.html" target="_blank">Delhi eases Covid-19 curbs further: Bars to reopen tomorrow </a></strong></p>.<p>According to an official of Madhukar Rainbow Children's Hospital, there is a delay on the part of the suppliers.</p>.<p>"We are expecting (roll out) next week," he said.</p>.<p>Fortis Healthcare, which had said it would make Sputnik V available at its Gurgaon and Mohali hospitals from Saturday, also has not started administering the Russian vaccine so far.</p>.<p>"The roll out did not happen on Saturday. We expect there will be some clarity on Monday," an official said.</p>.<p>The Centre has fixed the price of the vaccine at Rs 1,145 per dose. The maximum price of Covishield for private Covid-19 Vaccination Centres (CVCs) has been fixed at Rs 780 per dose, while that of Covaxin is Rs 1,410 per dose.</p>.<p>Russia's Gamaleya National Research Institute of Epidemiology and Microbiology has developed Sputnik V and the Russian Direct Investment Fund (RDIF) is marketing it globally.</p>.<p>Hyderabad-based Dr Reddy's Laboratories, the marketing partner for the vaccine in the country, has been importing the shots from Russia. </p>.<p>Over a period of time, the vaccine is also going to be manufactured in India. </p>.<p>Sputnik V uses two different viruses that cause the common cold (adenovirus) in humans. It employs a different vector for each of the two shots, given 21 days apart.</p>.<p>According to Gamaleya and the RDIF, Sputnik V has demonstrated an efficacy rate of 92 per cent. </p>